Core Viewpoint - The U.S. FDA has identified cases of liver injury linked to Amgen's drug Tavneos, prompting a warning for healthcare providers to monitor patients closely and discontinue treatment if liver damage is suspected [1][2]. Group 1: FDA Findings - The FDA reported 76 cases of drug-induced liver injury associated with Tavneos, including seven cases of vanishing bile duct syndrome, which can lead to permanent liver damage [2]. - Among the reported cases, there were eight fatalities [2]. Group 2: Regulatory Scrutiny - The safety warning adds to the regulatory scrutiny surrounding Tavneos, which is approved for treating ANCA-associated vasculitis, a rare autoimmune disease [3]. - In January, the FDA requested Amgen to voluntarily withdraw Tavneos due to concerns about the integrity of primary endpoint data from a late-stage trial involving 331 patients [3][4]. Group 3: Company Response - Amgen declined to withdraw Tavneos, asserting confidence in the drug's benefit-risk profile and indicating ongoing collaboration with the FDA [4]. - The median time to onset of drug-induced liver injury was reported as 46 days after starting treatment [4]. Group 4: International Regulatory Actions - While Tavneos labels in Europe and Australia mention post-marketing cases of vanishing bile duct syndrome, the U.S. prescribing information does not currently include this warning [5]. - The European Medicines Agency has initiated a review of Tavneos due to emerging concerns regarding data integrity [5].

Core Viewpoint - The U.S. FDA has mandated updates to the prescribing information for certain Parkinson's disease treatments, specifically those containing carbidopa or levodopa, to include warnings about the potential risk of seizures associated with vitamin B6 deficiency [1][2]. Group 1: FDA Findings and Recommendations - The FDA identified 14 cases of seizures linked to vitamin B6 deficiency in patients using carbidopa or levodopa, with seizures typically starting in one part of the brain and potentially becoming severe and prolonged [3]. - Healthcare professionals are advised to evaluate vitamin B6 levels before initiating treatment with these drugs and to consider vitamin B6 supplementation if necessary [3]. Group 2: Drug Mechanism and Impact - Levodopa converts into dopamine in the brain, which helps improve movement in Parkinson's disease patients, while carbidopa ensures more levodopa reaches the brain by preventing its premature breakdown [4]. - The FDA noted that these drugs can deplete vitamin B6 levels during the conversion process of levodopa to dopamine, with carbidopa binding to the active form of vitamin B6, leading to further functional loss of the vitamin [4]. Group 3: Affected Companies - Companies such as Amneal Pharmaceuticals, AbbVie, Organon, and Novartis manufacture drugs containing carbidopa or levodopa, but they did not immediately respond to requests for comment regarding the FDA's announcement [5].

Dosing oneself with poorly researched drugs bought online is a risky pastime. But it is an increasingly popular one https://t.co/1ot0tGmaiOIllustration: Kyle Ellingson https://t.co/Z5p0FUaWy7 ...

Core Viewpoint - Eli Lilly and Co has issued a warning regarding safety risks associated with compounded tirzepatide products mixed with vitamin B12, highlighting the discovery of an impurity formed from this combination [1][2][3]. Group 1: Safety Concerns - Internal testing revealed significant levels of an impurity created through a chemical reaction between tirzepatide and vitamin B12 [2]. - The newly identified impurity raises concerns due to unknown health effects in humans, with no data on its influence on tirzepatide's interaction with GLP-1 and GIP receptors, potential toxicity, immune response, and pharmacokinetics [3]. - Compounded versions of tirzepatide are not subject to the same adverse event tracking as FDA-approved medicines, increasing the risk for patients [4]. Group 2: Regulatory and Market Issues - The company expressed concerns about mass-compounded versions of its tirzepatide medicines, Mounjaro and Zepbound, and supports FDA actions to limit the distribution of compounded anti-obesity drugs that may violate regulatory standards [5]. - Lilly criticized the marketing of "personalized" versions of tirzepatide by compounding pharmacies, which often use identical additives in bulk-produced products rather than customizing for individual patients [6]. Group 3: Additional Risks - Beyond vitamin B12, compounded tirzepatide products have been mixed with other substances such as glycine, pyridoxine, niacinamide, and carnitine, which have not undergone clinical testing [7]. - The company has identified other potential safety issues in compounded tirzepatide products, including bacterial contamination, elevated endotoxin levels, and additional impurities not found in its FDA-approved medicines [7]. - Lilly has encouraged the FDA to consider recalls of compounded tirzepatide products containing untested additives like vitamin B12 [8].

Core Viewpoint - Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and Kenvue, alleging that they knowingly concealed Tylenol's links to autism and ADHD, following unproven claims made by former President Donald Trump regarding the drug's safety during pregnancy [1][2]. Company Overview - Johnson & Johnson has been selling Tylenol for over 60 years, while Kenvue, which was spun off from Johnson & Johnson, has been selling the product since 2023 [2]. - Kenvue has consistently defended the safety of Tylenol, asserting that it is the safest pain reliever option for pregnant women [3]. Legal Context - The lawsuit comes five weeks after Donald Trump's controversial statement linking Tylenol use during pregnancy to autism, which lacks scientific backing [1]. - Johnson & Johnson has stated that Kenvue is responsible for all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol [3].

Core Insights - A recent study published in the journal Expert Opinion on Drug Safety indicates that the use of depot medroxyprogesterone acetate (DMPA), marketed as Depo-Provera by Pfizer, for over one year is linked to a 3.5-fold increased risk of developing intracranial meningioma compared to the combined birth control pill Ethinylestradiol/levonorgestrel [1][13] - The study analyzed data from 114 million unique individuals, highlighting significant safety concerns regarding long-term use of DMPA [1][13] - Pfizer is currently facing a multidistrict litigation (MDL No. 3140) in the USA, with over 550 lawsuits filed by women who developed meningiomas after using Depo-Provera for more than one year [2][13] Company Liability - The lawsuits allege that Pfizer was aware of the risks associated with DMPA and failed to provide adequate warnings or promote safer alternatives [3] - Despite acknowledging the risks and adding warning labels in Canada and Europe, Pfizer has not issued similar warnings in the United States, raising concerns about inconsistent global safety standards [3] - Law firms are exploring potential class actions in various jurisdictions, including Europe, Australia, South Africa, and Canada [4] Historical Context - Depo-Provera was originally developed in the 1950s as a cancer treatment and has been marketed as a contraceptive since 1969, despite prior evidence of its carcinogenic potential in animals [6] - The FDA has previously denied approval for the drug multiple times due to safety concerns before it was finally approved in the US in 1992 [6] - The FDA has also denied multiple Freedom of Information Act requests regarding communications with Pfizer about Depo-Provera, citing trade secrets [7] Market Impact - Approximately 24.5% of sexually active women in the US have used Depo-Provera in their lifetime, with 15% usage reported in the UK [5] - The study's findings may lead women to consider safer contraceptive options, potentially impacting the market for DMPA [5]